Overview

The Phosphodiesterase 5 Inhibitor Tadalafil as an Adjunct to Antidepressants in Major Depressive Disorder Patients

Status:
Recruiting
Trial end date:
2022-12-31
Target enrollment:
Participant gender:
Summary
Antidepressant-like effects of tadalafil to its ability to modulate transduction pathways responsible for neuroplasticity. Treatment with tadalafil was shown to be PKG-dependent and lead to increased expression of cGMP, pCREB, BDNF and VGF in the hippocampus and prefrontal cortex (PFC), brain areas relevant to mood disorders pathophysiology. Low-dose tadalafil improved both depressive symptoms in patients with erectile dysfunction.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Sadat City University
Treatments:
Tadalafil